Working Today

 For A Cure



About CavoGene

CavoGene Research
CavoGene Opportunities
CavoGene Products

CavoGene LifeSciences is committed to individuals worldwide who are impacted by various neurodegenerative diseases. We are dedicated to the discovery, development and commercialization of novel gene therapies that attenuate memory loss and increase synaptic neuroplasticity, such as Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and Traumatic Brain Injury.

Our team is currently testing a novel gene therapy platform initially targeting treatment of ALS, also known as Lou Gehrig's disease. Importantly, CavoGene’s gene therapy is distinct from all other gene therapies that are currently being developed since SynCav1 targets all forms of ALS, both familial (genetic, causes less than 10% of ALS) and sporadic (90%+ of all ALS patients). Our therapy is both neuroprotective and promotes functional neuroplasticity to restore neuronal function in order to improve the quality of life for individuals afflicted with ALS. For more information on this disease, please visit the ALS Association website.

SynCav1 Demonstrates In Vitro Efficacy in Human Neurons


• Neuron specific gene therapy that delivers Caveolin-1 to promote neuronal plasticity & synaptic communication to facilitate neuronal repair


Proof of Concept: SynCav1 treatment demonstrated significant increases in dendritic and axonal growth in human neurons derived from induced pluripotent stem cells (iPSCs)


image of Gene Therapy Control vs SynCav1 Treated


SynCav1: Mechanism of Action


SynCav1 and Synapse images


SynCav1 induces neuronal specific regenerative processes, facilitating neuronal repair and slowing neuronal degeneration

  1. Uses a neuron-specific synapsin promoter to drive Caveolin-1 over-expression in neurons

  2. Transgene expression increases neuroplasticity, resulting in improved motor function, longevity, memory, cognition and function in ALS mice and Alzheimer's Disease mice

  3. Delivered non-systemically using Adeno-Associated Virus (AAV)


CavoGene’s Competitive Advantage



Gene icon

Gene expression platform for multiple CNS and neurodegenerative diseases

icon of file charting

Validated animal data lead to long term diversified risk

icon of brain in head

Transition from research to IND-enabling studies for rapid commercialization

icon of working data cloud

Emphasis on protecting intellectual property and shareholder value

icon of secure lock

Significant potential for non-dilutive financing and partnering activities

icon of rising graph

Strategic financing, exit and liquidity options Multiple strategic partnerships

icon of columns
  • Exclusive license from UCSD

  • 2 issued patents with extensive claims & FTO

  • Non-Provisional PCT (2020 actionable date)

  • Gavrilovich, Dodd & Lindsey LLP (IP counsel)

  • Tucker Ellis, LLP (Corporate counsel)

illustration, section of a human brain



CavoGene Pipeline


UC San Diego logo

Boosting Caveolin in Neuronal Cell Membranes Helps ALS Mice Survive

Mar 27, 2019

UC San Diego School of Medicine researchers previously found that boosting a membrane protein called caveolin-1 specifically in neurons (dubbed "SynCav1") improved memory in older mice and enhanced their functional neuroplasticity — the ability to adapt to new situations and form new memories.


Crains Cleveland Business logo

Regenerative medicine growing strong in Northeast Ohio, elsewhere

Feb 10, 2019

Biotech company CavoGene LifeSciences has licensed a novel investigational gene therapy from the University of California San Diego and brought the technology across the country to Cleveland, where the six-month-old firm will be headquartered.


CISION PR NewsWire logo

CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders

Oct 23, 2018

GLEN BURNIE, Md., Oct. 23, 2018 /PRNewswire/ -- CavoGene LifeSciences has announced that it has licensed a novel investigational gene therapy for patients with neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), traumatic brain and spinal cord injury, and age-related cognitive decline. Currently, there is a large unmet medical need for these life-threatening conditions.


Contact Us


Contact Information

address marker 6958 Aviation Blvd., Suite H
Glen Burnie, MD 21061